Answers are grounded in this paper and cite their sources.
Due to the expanding range of “vaccine-controlled” infections and the consolidation of the vaccination calendar, the development and more frequent use of combined and multivalent vaccines for mass population vaccination has been becoming an urgent public health problem. The analysis of scientific literature showing the possibilities, advantages and prospects of using such vaccines within the framework of the National Calendar of Preventive vaccinations in the Russian Federation is carried out. The search for publications was carried out in the databases PubMed, Scopus, Elsevier and e-library as of February 2025. The widespread use of combined and multivalent vaccines is a priority tactic for successful vaccination to create robust, long-term collective immunity to socially significant infections. Numerous clinical studies have established high safety and immunogenicity rates of modern combined vaccines, and facts have been proven to refute myths about their negative impact on children’s development. They can reduce the number of injections, doctor visits and the level of psychological trauma associated with them, potential side effects post-immunization and economic costs, increase the level of public confidence and, accordingly, the percentage of vaccination coverage. The use of pentavaccines, including domestic preparations containing a cell-free pertussis component, diphtheria, tetanus toxoids, capsular polysaccharide of Haemophilus influenzae serotype b, as well as an inactivated polio vaccine or recombinant surface antigen of hepatitis B virus, has been becoming especially relevant for the immunization of children. In influenza immunoprophylaxis, preference is given to Russian-made multivalent subunit adjuvant tri- and quadrivalent vaccines. A domestic multivalent pneumococcal vaccine has also been developed. Until 2035, the strategy for developing immunoprophylaxis of infectious diseases in Russia involves expanding the National Calendar to 19 infections from the list of vaccinations for epidemic indications. Priority is given to the prevention of meningococcal and rotavirus infection using quadrivalent subunit vaccines and live pentavalent genetically engineered vaccine and chickenpox (a domestic drug is being tested) in combination with the measles-rubella-mumps vaccine, respectively. Clinical trials with a combined vaccine for preventing influenza and coronavirus infection providing protection against the SARS-CoV-2 virus and four seasonal strains of influenza viruses have begun.
No takes yet. Share an insight, caveat, or question.
Tyukavkina et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: